• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection
  • News
  • Opinion
  • About
  • Glossary
  • PV Forum

Big Data

Big Data and Pharmacovigilance: Where are We Going?

January 26, 2018 by Jose Rossello Leave a Comment

Everyone talks about “big data”, and how it is going to transform many industries, including healthcare. In a recent work, Bate, Reynolds, and Caubel analyze and describe the achievements of big data approaches in pharmacoepidemiology, improvement on quality of data for drug safety research, and the role of big data in relation to the identification of potential safety signals in post-market surveillance, that is, the impact of big data on quantitative signal evaluation and the identification of potentially new safety signals.

In pharmacovigilance and signal detection, we have moved quickly from manual, paper-based methods for signal detection to spontaneous reporting systems that require electronic submission, but allow quantitative and qualitative analyses as part of signal management systems.

According to the authors:

While the core of regulated pharmacovigilance practice still centers on the collection of individual case safety reports, change is occurring, in part as a result of Big Data approaches. The greatest change in pharmacovigilance analytics being applied today, and the one most connected to the Big Data revolution, is the more sophisticated use of observational data, as evidenced by pharmacoepidemiologic studies conducted across multiple databases and the development of large networks of observational databases of Electronic Healthcare Records in North America.

The new pharmacovigilance analytics will go beyond safety assessment. It will provide value for research too. Examples will be comparative effectiveness studies, pragmatic trials or investigational trials in real-world settings. The FDA Sentinel Initiative is a clear example of this new approach.

The authors also talk about what is known as hypothesis-free signal detection with its advantages and limitations, consumer wearable technology for pharmacoepidemiologic research, the new data streams and technologies as a source for identifying potential new safety signals, and the need to critically evaluate the impact of innovative data sources and techniques.

For more information check out the complete article from Therapeutic Advances in Drug Safety.

Read the source article here: The hope, hype and reality of Big Data for pharmacovigilance.

Jose Rossello
Jose Rossello

Filed Under: Big Data

Primary Sidebar

Subscribe in a reader

Featured News / Posts

Analysis Of Textual Data May Complement Traditional Pharmacovigilance

According to a well-written systematic review on the application of natural … [Read More...] about Analysis Of Textual Data May Complement Traditional Pharmacovigilance

Machine Learning and Pharmacovigilance

Machine learning (ML) is becoming increasingly available to everyone, including … [Read More...] about Machine Learning and Pharmacovigilance

Post-Randomization vs On Treatment Made All the Difference

Post-Randomization vs On Treatment Made All the Difference

The Food and Drug Administration (FDA) recently requested withdraw of Belviq® … [Read More...] about Post-Randomization vs On Treatment Made All the Difference

Pharmacovigilance Audits/Inspections and PV Analytics!

Disclaimer: This article is written by a Safety Physician to provide … [Read More...] about Pharmacovigilance Audits/Inspections and PV Analytics!

Artificial Intelligence in pharmacovigilance? What a challenge!

Abstract Pharmaceutical industry, and more particularly pharmacovigilance, … [Read More...] about Artificial Intelligence in pharmacovigilance? What a challenge!

Knowledge Graphs,  Semantic Web and Drug Safety

Knowledge Graphs, Semantic Web and Drug Safety

Second part of: Mining PubMed for Drug Induced Acute Kidney Injury When I … [Read More...] about Knowledge Graphs, Semantic Web and Drug Safety

Review of Safety in FDA Medical Reviews

Review of Safety in FDA Medical Reviews

Analysis of the latest review of safety sections for new drug applications (NDAs … [Read More...] about Review of Safety in FDA Medical Reviews

Mining PubMed for Drug Induced Acute Kidney Injury

Mining PubMed for Drug Induced Acute Kidney Injury

Enhancing signal detection capabilities beyond regular literature … [Read More...] about Mining PubMed for Drug Induced Acute Kidney Injury

Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance

As drug safety and pharmacovigilance organizations develop more sophisticated … [Read More...] about Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

Peter J Pitts, President of the Center for Medicine in the Public Interest, and … [Read More...] about The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

  • Disproportional Recording vs Disproportional Reporting
  • Deep Learning, Machine Learning, and Artificial Intelligence – What are the Differences?
  • How Organizations Use Social Media For Pharmacovigilance

RSS From Nature journal

  • Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice
  • Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
  • Effect of date molasses on levetiracetam pharmacokinetics in healthy rats
  • Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
  • Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study

Copyright © 2023 · News Pro on Genesis Framework · WordPress · Log in